Editor’s note: A recording of the conversation is embedded below.
Nearly two dozen biopharmaceutical entities have signed on to be a part of the Covid R&D alliance, a coalition to pool resources and accelerate research on how to best combat the pandemic.
“the objectives are pretty straightforward. if we can come together, can we move things along faster than we would have done,” said Yvonne Greenstreet, chief operating officer of Alynylam, in a STAT+ Conversation this week. Greenstreet was joined by David Reese, executive vice president of research and development at Amgen, and Andrew Plump, president of research and development at Takeda.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect